APAC Leber Congenital Amaurosis Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-24
- Report ID: 143401
- Pages: 225
-
Format:
Short Description
Asia-Pacific Leber Congenital Amaurosis Market, By Disease (Infantile Type, Juvenile Type and Other), Type (Therapy and Diagnosis), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Home Healthcare and Others), Distribution Channel (Direct Tender and Retail Sales) Country (Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific) Industry Trends and Forecast to 2029
Market Definition:
Leber congenital amaurosis (LCA) is defined as a type of disorder of the eye which mainly affects the retina. Retina is the specific tissue at the back of the eye responsible for the detection of light and colour.
Leber congenital amaurosis (LCA) is a rare inherited eye disease that appears at birth or in the first few months of life. It affects about 1 in 40,000 new-borns. People with this disorder typically have severe visual impairment beginning in infancy. The visual impairment tends to be stable, although it may worsen very slowly over time.
Market Segmentation:
Asia-Pacific leber congential amaurosis market is categorized into four notable segments which are based on disease type, type, end user and distribution channel.
On the basis of disease type, the leber congenital amaurosis market is segmented into infantile type, juvenile type, and others.
On the basis of type, the congenital amaurosis market is segmented into diagnosis and therapy.
On the basis of end user, the leber congenital amaurosis market is segmented into hospitals, specialty clinics, ambulatory surgical centers, home healthcare, and others.
On the basis of distribution channel, the leber congenital amaurosis market is segmented into hospital pharmacies, retail pharmacies and others.
Market Players
The key market players for Asia-Pacific leber congential amaurosis market are listed below:
Invitae Corporation
Spark Therapeutics, Inc.,
LKC TECHNOLOGIES, INC,
CENTOGENE N.V.,
Optos, Metrovision,
Blueprint Genetics Oy (A Subsidiary of Quest Diagnostics),
CD Genomics,
ProQR Therapeutics,
OCUGEN, INC.,
MeiraGTx Limited,
Coave Therapeutics,
IVERIC bio, Inc.
Atsena Therapeutics
Editas Medicine
Eluminex Biosciences
Okuvision
Astellas Pharma Inc.
Allergan (A Subsidiary of Abbvie Inc.)
AGTC
Gyroscope Therapeutics Limited
SparingVision
Kubota Pharmaceutical Holdings Co. Ltd.
REGENXBIO Inc
TABLE OF CONTENTS
1 INTRODUCTION 22
1.1 OBJECTIVES OF THE STUDY 22
1.2 MARKET DEFINITION 22
1.3 OVERVIEW OF ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET 22
1.4 LIMITATIONS 23
1.5 MARKETS COVERED 24
2 MARKET SEGMENTATION 27
2.1 MARKETS COVERED 27
2.2 GEOGRAPHICAL SCOPE 28
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 CURRENCY AND PRICING 29
2.5 DBMR TRIPOD DATA VALIDATION MODEL 30
2.6 MULTIVARIATE MODELLING 33
2.7 DISEASE TYPE LIFELINE CURVE 33
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
2.9 DBMR MARKET POSITION GRID 35
2.10 MARKET END USER COVERAGE GRID 36
2.11 VENDOR SHARE ANALYSIS 37
2.12 SECONDARY SOURCES 38
2.13 ASSUMPTIONS 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHTS 42
4.1 PIPELINE ANALYSIS FOR ASIA PACIFIC LEBER CONGENTIAL AMAUROSIS MARKET 44
4.2 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: REGULATIONS 46
4.3 PESTEL ANALYSIS 49
4.4 PORTERS FIVE FORCES 50
5 EPIDEMIOLOGY 51
6 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, MARKET OVERVIEW 52
6.1 DRIVERS 54
6.1.1 INCREASE IN INCIDENCE AND PREVALENCE OF RPE65 GENE-MEDIATED IN RETINAL DISEASES 54
6.1.2 INCREASE IN PIPELINE PRODUCTS AND CLINICAL TRIALS 57
6.1.3 INCREASE IN STRATEGIC INITIATIVE BY KEY PLAYER 63
6.2 RESTRAINTS 64
6.2.1 LACK OF QUALIFIED PROFESSIONALS 64
6.2.2 HIGH COSTS ASSOCIATED WITH TREATMENT AND PROCEDURE 65
6.3 OPPORTUNITIES 66
6.3.1 INCREASE IN GOVERNMENT INITIATIVES TOWARD LEBER CONGENITAL AMAUROSIS 66
6.3.2 INCREASE IN THE TREATMENT-SEEKING RATE 66
6.3.3 FAVOURABLE REIMBURSEMENT POLICIES FOR THE TREATMENT 67
6.4 CHALLENGES 68
6.4.1 RISKS ASSOCIATED WITH LEBER CONGENITAL AMAUROSIS GENE THERAPY 68
6.4.2 STRINGENT GOVERNMENT REGULATIONS FOR GENE THERAPY PRODUCTS 68
7 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY DISEASE TYPE 69
7.1 OVERVIEW 70
7.2 INFANTILE TYPE 73
7.3 JUVENILE TYPE 73
7.4 OTHERS 74
8 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY TYPE 75
8.1 OVERVIEW 76
8.2 THERAPY 79
8.2.1 GENE THERAPY 80
8.2.1.1 LUXTURNA 80
8.2.2 RETINAL PROSTHETIC 80
8.2.3 NEUROPROTECTIVE AGENTS 80
8.2.3.1 VITAMIN A PALMITATE 81
8.2.3.2 DOCOSAHEXAENOIC ACID 81
8.2.3.3 LUTEIN 81
8.2.3.4 OTHERS 81
8.2.4 OTHERS 81
8.3 DIAGNOSIS 82
8.3.1 CLINICAL DIAGNOSIS 83
8.3.1.1 ELECTROPHYSIOLOGICAL TESTS 83
8.3.1.1.1 FULL-FIELD ELECTRORETINOGRAM (ERG) 84
8.3.1.1.2 DARK ADAPTOMETRY (DA) 84
8.3.1.2 RETINAL IMAGING 84
8.3.1.2.1 OPTICAL COHERENCE TOMOGRAPHY (OCT) 84
8.3.1.2.2 FUNDUS AUTOFLUORESCENCE 85
8.3.1.2.3 SCANNING LASER OPHTHALMOSCOPY (SLO) 85
8.3.1.2.4 ADAPTIVE OPTICS (AO) IMAGING 85
8.3.1.2.5 CONVENTIONAL COLOR FUNDUS IMAGING 85
8.3.1.3 VISUAL FIELD TEST 85
8.3.1.3.1 COMPUTERIZED VISUAL FIELD TESTS 85
8.3.1.3.2 MANUAL FIELD TEST 85
8.3.1.4 CLINICAL EYE EXAMINATION 86
8.3.1.4.1 SLIT LAMP 86
8.3.1.4.2 INDIRECT OPHTHALMOSCOPY 86
8.3.1.4.3 REFRACTION TEST 86
8.3.1.4.4 DILATION EXAM 86
8.3.1.5 OTHERS 86
8.3.2 GENETIC DIAGNOSIS 87
9 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY END USER 88
9.1 OVERVIEW 89
9.2 HOSPITALS 92
9.3 SPECIALITY CLINICS 93
9.4 AMBULATORY SURGICAL CENTERS 94
9.5 HOME HEALTHCARE 95
9.6 OTHERS 96
10 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY DISTRIBUTION CHANNEL 97
10.1 OVERVIEW 98
10.2 RETAIL SALES 101
10.2.1.1 HOSPITAL PHARMACIES 102
10.2.1.2 RETAIL PHARMACIES 102
10.2.1.3 OTHERS 102
10.3 DIRECT TENDER 102
11 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET, BY REGION 103
11.1 ASIA-PACIFIC 104
11.1.1 CHINA 112
11.1.2 JAPAN 116
11.1.3 INDIA 120
11.1.4 SOUTH KOREA 124
11.1.5 AUSTRALIA 128
11.1.6 SINGAPORE 132
11.1.7 THAILAND 136
11.1.8 INDONESIA 140
11.1.9 PHILIPPINES 144
11.1.10 MALAYSIA 148
11.1.11 VIETNAM 153
11.1.12 REST OF ASIA-PACIFIC 157
12 ASIA PACIFIC LEBER CONGENITAL AMAUROSIS MARKET: COMPANY LANDSCAPE 158
12.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 158
13 SWOT ANALYSIS 159
14 COMPANY PROFILE 160
14.1 SPARK THERAPEUTICS, INC 160
14.1.1 COMPANY SNAPSHOT 160
14.1.2 COMPANY SHARE ANALYSIS 160
14.1.3 PRODUCT PORTFOLIO 161
14.1.4 RECENT DEVELOPMENT 161
14.1.4.1 EU AUTHORIZATION 161
14.2 OPTOS 162
14.2.1 COMPANY SNAPSHOT 162
14.2.2 COMPANY SHARE ANALYSIS 162
14.2.3 PRODUCT PORTFOLIO 163
14.2.4 RECENT DEVELOPMENT 163
14.2.4.1 PRODUCT APPROVAL 163
14.3 CD GENOMICS 164
14.3.1 COMPANY SNAPSHOT 164
14.3.2 COMPANY SHARE ANALYSIS 164
14.3.3 PRODUCT PORTFOLIO 165
14.3.4 RECENT DEVELOPMENT 165
14.4 BLUEPRINTS GENETICS OY (A SUBSIDIARY OF QUEST DIAGNOSTICS) 166
14.4.1 COMPANY SNAPSHOT 166
14.4.2 REVENUE ANALYSIS 166
14.4.3 COMPANY SHARE ANALYSIS 167
14.4.4 PRODUCT PORTFOLIO 167
14.4.5 RECENT DEVELOPMENTS 167
14.4.5.1 COLLABORATION 167
14.5 LKC TECHNOLOGIES, INC 168
14.5.1 COMPANY SNAPSHOT 168
14.5.2 COMPANY SHARE ANALYSIS 168
14.5.3 PRODUCT PORTFOLIO 169
14.5.4 RECENT DEVELOPMENT 169
14.5.4.1 PRODUCT APPROVAL 169
14.5.5 PRODUCT APPROVAL 169
14.6 AGTC 170
14.6.1 COMPANY SNAPSHOT 170
14.6.2 REVENUE ANALYSIS 170
14.6.3 PRODUCT PORTFOLIO 171
14.6.4 RECENT DEVELOPMENTS 171
14.6.4.1 AGREEMENT 171
14.7 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.) 172
14.7.1 COMPANY SNAPSHOT 172
14.7.2 REVENUE ANALYSIS 172
14.7.3 PRODUCT PORTFOLIO 173
14.7.4 RECENT DEVELOPMENTS 173
14.8 ASTELLAS PHARMA INC. 174
14.8.1 COMPANY SNAPSHOT 174
14.8.2 REVENUE ANALYSIS 174
14.8.3 PRODUCT PORTFOLIO 175
14.8.4 RECENT DEVELOPMENT 175
14.9 ATSENA THERAPEUTICS 176
14.9.1 COMPANY SNAPSHOT 176
14.9.2 PRODUCT PORTFOLIO 176
14.9.3 RECENT DEVELOPMENT 176
14.10 CENTOGENE N.V. 177
14.10.1 COMPANY SNAPSHOT 177
14.10.2 REVENUE ANALYSIS 177
14.10.3 PRODUCT PORTFOLIO 178
14.10.4 RECENT DEVELOPMENT 178
14.10.4.1 PRODUCT LAUNCH 178
14.11 COAVE THERAPEUTICS 179
14.11.1 COMPANY SNAPSHOT 179
14.11.2 PRODUCT PORTFOLIO 179
14.11.3 RECENT DEVELOPMENT 179
14.12 EDITAS MEDICINE 180
14.12.1 COMPANY SNAPSHOT 180
14.12.2 REVENUE ANALYSIS 180
14.12.3 PRODUCT PORTFOLIO 181
14.12.4 RECENT DEVELOPMENTS 181
14.12.4.1 DATA & TRAIL DATA PRESENTATION 181
14.13 ELUMINEX BIOSCIENCES 182
14.13.1 COMPANY SNAPSHOT 182
14.13.2 PRODUCT PORTFOLIO 182
14.13.3 RECENT DEVELOPMENT 182
14.14 GYROSCOPE THERAPEUTICS LIMITED 183
14.14.1 COMPANY SNAPSHOT 183
14.14.2 PRODUCT PORTFOLIO 183
14.14.3 RECENT DEVELOPMENTS 183
14.15 INVITAE CORPORATION 185
14.15.1 COMPANY SNAPSHOT 185
14.15.2 REVENUE ANALYSIS 185
14.15.3 PRODUCT PORTFOLIO 186
14.15.4 RECENT DEVELOPMENTS 186
14.15.4.1 NEW FACILITY 186
14.15.4.2 EXPANSION 186
14.16 IVERIC BIO. 187
14.16.1 COMPANY SNAPSHOT 187
14.16.2 PRODUCT PORTFOLIO 187
14.16.3 RECENT DEVELOPMENT 187
14.17 KUBOTA PHARMACEUTICAL HOLDINGS CO., LTD. 188
14.17.1 COMPANY SNAPSHOT 188
14.17.2 REVENUE ANALYSIS 188
14.17.3 PRODUCT PORTFOLIO 189
14.17.4 RECENT DEVELOPMENTS 189
14.18 MEIRAGTX LIMITED 190
14.18.1 COMPANY SNAPSHOT 190
14.18.2 PRODUCT PORTFOLIO 190
14.18.3 RECENT DEVELOPMENT 190
14.19 METROVISION 192
14.19.1 COMPANY SNAPSHOT 192
14.19.2 PRODUCT PORTFOLIO 192
14.19.3 RECENT DEVELOPMENT 192
14.19.3.1 FDA CLEARANCE APPROVAL 192
14.20 OCUGEN INC. 193
14.20.1 COMPANY SNAPSHOT 193
14.20.2 PRODUCT PORTFOLIO 193
14.20.3 RECENT DEVELOPMENT 193
14.21 OKUVISION 194
14.21.1 COMPANY SNAPSHOT 194
14.21.2 PRODUCT PORTFOLIO 194
14.21.3 RECENT DEVELOPMENTS 194
14.21.3.1 APPROVAL 194
14.22 PROQR THERAPEUTICS 195
14.22.1 COMPANY SNAPSHOT 195
14.22.2 PRODUCT PORTFOLIO 195
14.22.3 RECENT DEVELOPMENTS 195
14.23 REGENXBIO INC. 196
14.23.1 COMPANY SNAPSHOT 196
14.23.2 REVENUE ANALYSIS 196
14.23.3 PRODUCT PORTFOLIO 197
14.23.4 RECENT DEVELOPMENTS 197
14.24 SPARINGVISION 198
14.24.1 COMPANY SNAPSHOT 198
14.24.2 PRODUCT PORTFOLIO 198
14.24.3 RECENT DEVELOPMENTS 198
15 QUESTIONNAIRE 199
16 RELATED REPORTS 202
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
